
WHAT IS CLAIMED IS:

1. A compound of Formula I:



I

or a pharmaceutically acceptable derivative thereof, wherein:

X is NR^1R^2, OR^3 or SR^4;

R^1 and R^2 are each independently H, alkyl, OR^5 or COR^6, or together with the nitrogen atom to which they are attached form heterocycloalkyl;

R^3 is alkyl or COR^7;

R^4 is H, alkyl or COR^8;

R^5 is H or alkyl;

R^6 is R^9, OR^{10} or $NR^{11}R^{12}$;

R^7-R^9 are each independently alkyl or aralkyl;

R^{10}-R^{12} are each independently H, alkyl or aralkyl;

Y is H or OH; and

(i) Z is O and ⎓ is a single bond; or (ii) Z is absent and ⎓ is a double bond.

2. The compound of claim 1, wherein R^1 and R^2 are each independently H, methyl, ethyl, C(O)-($C_{2\text{-}4}$alkylene)-CO-W where W is OR^{13} or $NR^{14}R^{15}$, or C(O)-CH(V)-CH_3 where V is OR^{16} or $NR^{17}R^{18}$, or together with the nitrogen atom to which they are attached form piperazinyl; R^{13} and R^{16} are each independently H or methyl; and R^{14}, R^{15}, R^{17} and R^{18} are each independently H, methyl, hydroxy or methoxy.

3. The compound of any one of claims 1-2, wherein R^1 is H, methyl, ethyl, $C(O)CH_2CH_2COOH$, $C(O)CH_2CH_2CH_2COOH$, $C(O)CH_2CH_2CH_2CH_2COOH$, $C(O)CH_2CH_2CH_2COOMe$, $C(O)CH_2CH_2CH_2CONHOH$, $C(O)CH_2CH_2CH_2CONHOMe$, C(O)-CH(OH)-CH_3, C(O)-CH(NH_2)-CH_3 or C(O)-CH(NMe_2)-CH_3; and R^2 is H or methyl; or R^1 and R^2 together with the nitrogen atom to which they are attached form 4-methyl-1-piperazinyl.

4. The compound of claim 1, wherein R^3 is methyl or C(O)-alkyl, where the alkyl is optionally substituted.

5. The compound of any one of claim 1 or 4, wherein R^3 is methyl, C(O)-CH(NHMe)-CH_3 or C(O)-CH(NHAc)-CH_3.

6. The compound of claim 1, wherein R^4 is C(O)Me; and R^5 is H or methyl.

7. The compound of claim 1, wherein R^6 is CH_2CH_2COOH, $CH_2CH_2CH_2COOH$, $CH_2CH_2CH_2CH_2COOH$, $CH_2CH_2CH_2COOMe$, $CH_2CH_2CH_2CONHOH$ or $CH_2CH_2CH_2CONHOMe$.

8. The compound of claim 1, wherein R^7 and R^8 are each independently methyl.


9. The compound of claim 1, wherein R^{10}-R^{12} are each independently H or methyl.

10. The compound of any one of claims 1-9, wherein Y is H, Z is absent and ⎓ is a double bond.

11. The compound of any one of claims 1-9, wherein Y is OH, Z is absent and ⎓ is a double bond.

12. The compound of any one of claims 1-9, wherein Y is H, Z is O and ⎓ is a single bond.

13. The compound of claim 1 having Formula II:



II

or a pharmaceutically acceptable derivative thereof, wherein:





R^1 is H or -COR^6; and





R^6 is -alkylene-COOH.





14. The compound of claim 13, wherein R^1 is -COR^6.





15. The compound of claim 13 or 14, wherein R^6 is $–(CR^{21}R^{22})_mCOOH$, where R^{21} and R^{22} are each independently H or alkyl; and m is an integer from 0-6.





16. The compound of any one of claims 1-15 selected from:



Compound	Structure
4 (R)-amino-verrucarin A	
5	
6	
7	

Compound	Structure
22	
24	
25	
52	


Compound	Structure
53	
54	
55	
56	

Compound	Structure
57	
58	
59	
62	

Compound	Structure
64	
65	
77	
78	

Compound	Structure
80	
81	


17. A compound of Formula III:



III

or a pharmaceutically acceptable derivative thereof, wherein X^1 is O or NH; D is absent or is -C(O)-$(CH_2)_{2\text{-}5}$-C(O)- or -O-NH-C(O)-$(CH_2)_{2\text{-}5}$-C(O)-; L is a linking group; Y is H or OH; and (i) Z is O and ⎓ is a single bond; or (ii) Z is absent and ⎓ is a double bond.

18. A compound of claim 17 that has Formula IV:



IV

or a pharmaceutically acceptable derivative thereof, wherein L is a linking group and n is an integer from 1 to 4.


19. The compound of claim 18, wherein n is 1, 2 or 3.


20. The compound of any one of claims 17-19, wherein L is a cleavable linker.


21. The compound of any one of claims 17-20, wherein L is an acid-labile linker, a hydrolysis-labile linker, an enzymatically cleavable linker, a reduction labile linker, or a self-immolative linker.


22. The compound of any one of claims 17-21, wherein L comprises or consists of val-cit-PAB, val-cit-MePAB (val-cit-(p-amino-α-benzyloxy)), AC (6-aminocaproyl), MC (6-maleimidocaproyl), MC-val-cit-PAB, AC-val-cit-PAB, MC-val-cit-MePAB, AC-val-cit-MePAB, or AC-GGFG-CH_2-.

23. The compound of any one of claims 17-22, having one of the formulae:





AC-val-cit-PAB-O
O
n
N
H
O
O
O
O
O
O
O
O
O
H
H
O






MC-val-cit-MePAB-O
O
n
N
H
O
O
O
O
O
O
O
O
O
H
H
O











24. The compound of any one of claims 17-19, wherein L is a non-cleavable linker.





25. The compound of any one of claims 17-24 selected from:






Compound	**Structure**
10a (n = 1)	





Compound	Structure
10b (n = 2)	
10c (n = 3)	
12a (n = 1)	
12b (n = 2)	





Compound	Structure
12c (n = 3)	
19a (n = 1)	
19b (n = 2)	
19c (n = 3)	



Compound	Structure
21a (n = 1)	
21b (n = 2)	
21c (n = 3)	
37	

Compound	Structure
46	
53	
70a	 Major diastereomer
70b	 Minor Diastereomer

Compound	Structure
74	
75	
76	
88	
91	

Compound	Structure
97	
95	
101	
106	

Compound	Structure
109	
114	
118	
121	

Compound	Structure
124	
126	

26. A compound of Formula V:

$Z\text{-}(L\text{-}X)_v$ **V**

or a pharmaceutically acceptable derivative thereof, wherein:

Z is an anti-influenza antigen-binding domain, an anti-SARS-CoV-2 antigen-binding domain, or an anti-ebola virus antigen-binding domain;

L is a linking group;

X is a verrucarin A derivative; and

v is an integer from 1 to 12.

27. The compound of claim 26, wherein X is radical formed by removal of an H from a compound of any one of claims 1-25.

28. The compound of any one of claims 26-27, wherein -L-X is radical formed by removal of an H from a compound of any one of claims 17-25.

29. The compound of any one of claims 26-28, wherein v is an integer from 1 to 10, from 1 to 8, from 1 to 6, or from 1 to 4.

30. The compound of any one of claims 26-29, wherein v is 1, 2, 3, 4, 5, 6, 7 or 8.


31. The compound of any one of claims 26-30, wherein Z comprises an antibody heavy chain and further includes a peptide tag at the C-terminus of the antibody heavy chain, wherein the peptide tag is ELQRP, LLQG, LLQGG, LLQLLQG, LLQYQG, LLQGA,


LLQGSG, SLLQG, LQG, LLQLQ, LLQLLQ, LLQGR, LLQYQGA, LQGG, LGQG or LLQLLQGA.

32. The compound of any one of claims 26-31, wherein Z comprises two antibody heavy chains and a peptide tag at the C-terminus of each antibody heavy chain.

33. The compound of any one of claims 31-32, wherein the peptide tag is the pentapeptide sequence LLQGA or ELQGP.

34. The compound of any one of claims 26-33, having one of the following formulae:





35. A pharmaceutical composition, comprising a compound of any one of claims 1-34 and a pharmaceutically acceptable carrier.

36. Use of a compound of any one of claims 1-34 or the composition of claim 35 in the manufacture of a medicament for treating influenza infection in a subject.

37. The use of claim 36, wherein the influenza is influenza A.

38. Use of a compound of any one of claims 1-34 or the composition of claim 35 in the manufacture of a medicament for treating SARS-CoV-2 infection in a subject.

39. The use of claim 38, wherein the SARS-CoV-2 is an omicron variant.

40. Use of a compound of any one of claims 1-34 or the composition of claim 35 in the manufacture of a medicament for treating ebola infection in a subject.